Structure Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Structure Therapeutics with an Overweight rating and $58 price target. The analyst sees a “substantial opportunity” in the company’s wholly owned pipeline of oral, small molecule GPCR agents addressing high unmet need indications. The firm says GSBR-1290 has seven points of differentiation versus other oral GLP-1Rs and has “major potential in the wide open obesity market.”